CL2011001284A1 - Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab. - Google Patents

Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab.

Info

Publication number
CL2011001284A1
CL2011001284A1 CL2011001284A CL2011001284A CL2011001284A1 CL 2011001284 A1 CL2011001284 A1 CL 2011001284A1 CL 2011001284 A CL2011001284 A CL 2011001284A CL 2011001284 A CL2011001284 A CL 2011001284A CL 2011001284 A1 CL2011001284 A1 CL 2011001284A1
Authority
CL
Chile
Prior art keywords
vaccine
produce
pathogens
toxin
procedure
Prior art date
Application number
CL2011001284A
Other languages
English (en)
Inventor
Jessica Reineke
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42022135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CL2011001284A1 publication Critical patent/CL2011001284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procedimiento para la producción de vacunas contra patógenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patógenos que producen toxinas ab.
CL2011001284A 2008-12-03 2011-05-31 Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab. CL2011001284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170591 2008-12-03

Publications (1)

Publication Number Publication Date
CL2011001284A1 true CL2011001284A1 (es) 2011-09-16

Family

ID=42022135

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001284A CL2011001284A1 (es) 2008-12-03 2011-05-31 Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab.

Country Status (18)

Country Link
US (1) US20110243991A1 (es)
EP (1) EP2373332A1 (es)
JP (1) JP2012510497A (es)
KR (1) KR20110100189A (es)
CN (1) CN102238960B (es)
AR (1) AR074455A1 (es)
AU (1) AU2009324180A1 (es)
BR (1) BRPI0922219A2 (es)
CA (1) CA2737403A1 (es)
CL (1) CL2011001284A1 (es)
CO (1) CO6390040A2 (es)
MX (1) MX2011005758A (es)
RU (1) RU2011126602A (es)
SG (1) SG171934A1 (es)
TW (1) TW201026852A (es)
UA (1) UA105508C2 (es)
WO (1) WO2010063693A1 (es)
ZA (1) ZA201101645B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US8909605B1 (en) 2013-02-28 2014-12-09 Emc Corporation Method and system for accelerating data movement using change information concerning difference between current and previous data movements
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
CN109865135A (zh) * 2019-03-18 2019-06-11 宁波大学 一种银鲳美人鱼发光杆菌和灿烂弧菌联合灭活疫苗
KR102376876B1 (ko) * 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
CN1195993A (zh) * 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen

Also Published As

Publication number Publication date
SG171934A1 (en) 2011-07-28
KR20110100189A (ko) 2011-09-09
EP2373332A1 (en) 2011-10-12
MX2011005758A (es) 2011-06-28
AR074455A1 (es) 2011-01-19
AU2009324180A1 (en) 2010-06-10
CO6390040A2 (es) 2012-02-29
CN102238960B (zh) 2014-04-23
CN102238960A (zh) 2011-11-09
CA2737403A1 (en) 2010-06-10
JP2012510497A (ja) 2012-05-10
TW201026852A (en) 2010-07-16
US20110243991A1 (en) 2011-10-06
WO2010063693A1 (en) 2010-06-10
UA105508C2 (uk) 2014-05-26
ZA201101645B (en) 2011-11-30
BRPI0922219A2 (pt) 2018-10-23
RU2011126602A (ru) 2013-01-10

Similar Documents

Publication Publication Date Title
CL2011001284A1 (es) Procedimiento para la produccion de vacunas contra patogenos bacterianos que producen una toxina ab; vacuna que comprende el toxoide a y/o b de clostridium; uso de dicha vacuna contra infecciones de patogenos que producen toxinas ab.
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
CL2016001235A1 (es) Cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados-formulaciones y usos (divisional solicitud 467-2014).
UY32933A (es) Sistema de expresión periplásmico
MX376284B (es) Una composición que comprende un agente antibiótico y un agente dispersante o un agente antiadhesivo.
MD3359172T2 (ro) Compoziții care conțin tulpini bacteriene
CR11812A (es) Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso
CO6331298A2 (es) Vacunas contra coccidiosis
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
MX2010000864A (es) Vacuna de celulas enteras estafilococcicas inactivadas.
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
MX2013002058A (es) Composicion de tratamiento para cabello.
CA2798214C (en) Vaccine against beta-herpesvirus infection and use thereof
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
MX2019005499A (es) Atenuacion de virulencia bacteriana mediante atenuacion de transporte de folato bacteriano.
WO2010034974A3 (en) Tuberculosis vaccines targeted to cd40
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
PH12016500946A1 (en) Composition for preventing and curing mycoplasma infection
UY31437A1 (es) Vacuna de mycoplasma bovis y métodos de uso de la misma
CL2009001506A1 (es) Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
CL2011002649A1 (es) Uso de un aerosol que comprende levofloxacina u ofloxacina para preparar un medicamento util para el tratamiento de una infeccion bacteriana pulmonar.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
AR056733A1 (es) Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
BR112016012393A8 (pt) vacina, e, uso de uma combinação de um vírus prrs atenuado vivo e um antígeno de lawsonia intracellularis inativado